Status:
COMPLETED
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
Lead Sponsor:
Genentech, Inc.
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This study will assess the efficacy and safety of different treatment regimens of rituximab (MabThera®/Rituxan®), corticosteroids, and placebo, combined with methotrexate (MTX), in patients with activ...
Eligibility Criteria
Inclusion
- Eligibility criteria include, but are not limited to the following:
- Are between the ages of 18 and 80 years.
- Have been diagnosed with rheumatoid arthritis for at least 6 months.
- Have failed treatment (lack of efficacy) with at least 1 but no more than 5 disease-modifying anti-rheumatic drugs or biologics (other than methotrexate).
Exclusion
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
465 Patients enrolled
Trial Details
Trial ID
NCT00074438
Start Date
June 1 2003
End Date
July 1 2011
Last Update
May 9 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.